FDA
-
-
-
-
-
-
-
Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum™ in the US
-
-
-
-
-
-
-
Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company’s Lead Product Candidate, Vicineum™
-
-
-
-
-
-
-
22nd Century Group (XXII) Announces CFO Transition
-
-
-
-
-
-
-
After-Hours Stock Movers 10/19: (SESN) (AKRO) (LRN) Higher; (ATIP) (WDFC) Lower (more...)
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Yalla, Sesen Bio, and loanDepot and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Sesen Bio (SESN) IV above 250 amid wide price movement
-
-
-
-
-
-
-
Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum™
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

